Anne Leselbaum

2.3k total citations · 1 hit paper
25 papers, 1.3k citations indexed

About

Anne Leselbaum is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Anne Leselbaum has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 7 papers in Physiology and 3 papers in Surgery. Recurrent topics in Anne Leselbaum's work include Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers), Respiratory and Cough-Related Research (11 papers) and Asthma and respiratory diseases (7 papers). Anne Leselbaum is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers), Respiratory and Cough-Related Research (11 papers) and Asthma and respiratory diseases (7 papers). Anne Leselbaum collaborates with scholars based in Spain, United States and Canada. Anne Leselbaum's co-authors include Silvio Danese, Julián Panés, Eran Goldin, Jean‐Frédéric Colombel, Damián García‐Olmo, Fernando de la Portilla, Jean Charles Grimaud, Marc Ferrante, Lili Kazemi-Shirazi and Gert Van Assche and has published in prestigious journals such as The Lancet, CHEST Journal and European Respiratory Journal.

In The Last Decade

Anne Leselbaum

23 papers receiving 1.3k citations

Hit Papers

Expanded allogeneic adipose-derived mesenchymal stem cell... 2016 2026 2019 2022 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial
    2016 738 citations Julián Panés, Damián García‐Olmo et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne Leselbaum Spain 9 567 479 469 291 262 25 1.3k
Wanda Maglione Italy 18 148 0.3× 202 0.4× 223 0.5× 192 0.7× 57 0.2× 38 1.1k
C Alvisi Italy 17 227 0.4× 714 1.5× 48 0.1× 337 1.2× 212 0.8× 34 1.2k
Daniela A. Moraes Brazil 13 156 0.3× 438 0.9× 57 0.1× 253 0.9× 323 1.2× 48 1.1k
Yoram Stern Israel 18 325 0.6× 278 0.6× 112 0.2× 51 0.2× 60 0.2× 38 747
Luca Calabrese Italy 23 355 0.6× 888 1.9× 110 0.2× 36 0.1× 102 0.4× 83 1.5k
Giovanni Amendola Italy 17 100 0.2× 175 0.4× 128 0.3× 434 1.5× 127 0.5× 38 991
Beth A Brillante United States 20 267 0.5× 178 0.4× 171 0.4× 21 0.1× 132 0.5× 27 1.2k
Héctor Guadalajara Spain 19 97 0.2× 814 1.7× 77 0.2× 261 0.9× 175 0.7× 56 1.3k
Irene Miniati Italy 20 237 0.4× 227 0.5× 57 0.1× 144 0.5× 37 0.1× 30 1.4k
Hymie Gordon United States 16 492 0.9× 662 1.4× 51 0.1× 70 0.2× 218 0.8× 29 1.7k

Countries citing papers authored by Anne Leselbaum

Since Specialization
Citations

This map shows the geographic impact of Anne Leselbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Leselbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Leselbaum more than expected).

Fields of papers citing papers by Anne Leselbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Leselbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Leselbaum. The network helps show where Anne Leselbaum may publish in the future.

Co-authorship network of co-authors of Anne Leselbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Leselbaum. A scholar is included among the top collaborators of Anne Leselbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Leselbaum. Anne Leselbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Panés, Julián, Damián García‐Olmo, Gert Van Assche, et al.. (2016). A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn's disease. 10. 3 indexed citations
3.
Vogelmeier, Claus, Pier Luigi Paggiaro, Jordi Dorca, et al.. (2016). Efficacy and safety of aclidinium/formoterolversussalmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal. 48(4). 1030–1039. 75 indexed citations
4.
Panés, Julián, Damián García‐Olmo, Gert Van Assche, et al.. (2016). Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. The Lancet. 388(10051). 1281–1290. 738 indexed citations breakdown →
5.
Fuhr, Rainard, et al.. (2015). Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed‐dose combination compared with individual components: A phase 1, open‐label, single‐dose study. Clinical Pharmacology in Drug Development. 5(2). 109–117. 7 indexed citations
6.
7.
8.
Make, Barry J., et al.. (2014). Long-term Safety of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate in Patients With Stable Moderate to Severe COPD. CHEST Journal. 145(3). 386A–386A. 7 indexed citations
9.
Singh, Dave, Paul Jones, Eric Bateman, et al.. (2014). Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study. CHEST Journal. 145(3). 375A–375A. 7 indexed citations
10.
D’Urzo, Anthony, et al.. (2014). The AUGMENT COPD Trial: Efficacy and Safety of a Fixed-Dose Combination of Aclidinium Bromide and Formoterol Fumarate in COPD Patients. CHEST Journal. 145(3). 426A–426A. 10 indexed citations
11.
12.
Bateman, Eric, et al.. (2014). Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies. 44. 285. 4 indexed citations
13.
D’Urzo, Anthony, Stephen I. Rennard, Edward Kerwin, et al.. (2014). One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study. 44. 286. 4 indexed citations
14.
15.
16.
17.
18.
Bronstein, Marcello D., Nina Rosa de Castro Musolino, Raquel S. Jallad, et al.. (2005). Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clinical Endocrinology. 63(5). 514–519. 46 indexed citations
19.
Chanson, Philippe, Anne Leselbaum, Joëlle Blumberg, & G Schaison. (2000). Efficacy and Tolerability of the Long-Acting Somatostatin Analog Lanreotide in Acromegaly. A 12-Month Multicenter Study of 58 Acromegalic Patients. Pituitary. 2(4). 269–276. 43 indexed citations
20.
Guérot, Emmanuel, et al.. (1995). Toxoplasma pericarditis in acquired immunodeficiency syndrome. Intensive Care Medicine. 21(3). 229–230. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wanda Maglione Breakdown of academic impact, for papers by C Alvisi Breakdown of academic impact, for papers by Daniela A. Moraes Breakdown of academic impact, for papers by Yoram Stern Breakdown of academic impact, for papers by Luca Calabrese Breakdown of academic impact, for papers by Giovanni Amendola Breakdown of academic impact, for papers by Beth A Brillante Breakdown of academic impact, for papers by Héctor Guadalajara Breakdown of academic impact, for papers by Irene Miniati Breakdown of academic impact, for papers by Hymie Gordon
Rankless by CCL
2026